Literature DB >> 25592834

Aberrant activation of AMP-activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis.

Yu-Ju Liu1, Li-Ming Lee2, Hsing-Lin Lai3, Yijuang Chern4.   

Abstract

Distorted mRNA metabolism contributes to amyotrophic lateral sclerosis (ALS). The human antigen R (HuR) is a major mRNA stabilizer. We report that abnormal localization of HuR was associated with enhanced AMP-activated protein kinase (AMPK) activity in the motor neurons of ALS patients. Activation of AMPK changed the location of HuR in mouse motor neurons and in a motor neuron cell line via phosphorylation of importin-α1. Stimulation of the A2A adenosine receptor normalized the AMPK-evoked redistribution of HuR. This suggests that aberrant activation of AMPK in motor neurons disrupts the normal distribution of HuR, which might imbalance RNA metabolism and contribute to ALS pathogenesis.
Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  A(2A) adenosine receptor; AMP-activated protein kinase; Amyotrophic lateral sclerosis; Human antigen R; Importin-α1; cAMP

Mesh:

Substances:

Year:  2015        PMID: 25592834     DOI: 10.1016/j.febslet.2014.12.029

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  16 in total

1.  Early ALS-type gait abnormalities in AMP-dependent protein kinase-deficient mice suggest a role for this metabolic sensor in early stages of the disease.

Authors:  Maxime Vergouts; Claudia Marinangeli; Caroline Ingelbrecht; Geraldine Genard; Olivier Schakman; Anthony Sternotte; André-Guilhem Calas; Emmanuel Hermans
Journal:  Metab Brain Dis       Date:  2015-07-09       Impact factor: 3.584

2.  Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles.

Authors:  Aymeric Ravel-Chapuis; Ali Al-Rewashdy; Guy Bélanger; Bernard J Jasmin
Journal:  Hum Mol Genet       Date:  2018-10-01       Impact factor: 6.150

Review 3.  AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis.

Authors:  Nirma D Perera; Bradley J Turner
Journal:  Neurochem Res       Date:  2015-07-23       Impact factor: 3.996

Review 4.  Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis.

Authors:  Andrew T Nelson; Davide Trotti
Journal:  Neurotherapeutics       Date:  2022-06-30       Impact factor: 6.088

Review 5.  Understanding and targeting the disease-related RNA binding protein human antigen R (HuR).

Authors:  Christopher W Schultz; Ranjan Preet; Teena Dhir; Dan A Dixon; Jonathan R Brody
Journal:  Wiley Interdiscip Rev RNA       Date:  2020-01-23       Impact factor: 9.957

Review 6.  What is "Hyper" in the ALS Hypermetabolism?

Authors:  Alberto Ferri; Roberto Coccurello
Journal:  Mediators Inflamm       Date:  2017-09-07       Impact factor: 4.711

Review 7.  Energy Homeostasis and Abnormal RNA Metabolism in Amyotrophic Lateral Sclerosis.

Authors:  Yu-Ju Liu; Po-Yi Tsai; Yijuang Chern
Journal:  Front Cell Neurosci       Date:  2017-05-04       Impact factor: 5.505

8.  The D2 Dopamine Receptor Interferes With the Protective Effect of the A2A Adenosine Receptor on TDP-43 Mislocalization in Experimental Models of Motor Neuron Degeneration.

Authors:  Chia-You Lai; Yu-Ju Liu; Hsing-Lin Lai; Hui-Mei Chen; Hung-Chi Kuo; Yu-Ping Liao; Yijuang Chern
Journal:  Front Neurosci       Date:  2018-03-20       Impact factor: 4.677

Review 9.  Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.

Authors:  Ágatha Oliveira-Giacomelli; Yahaira Naaldijk; Laura Sardá-Arroyo; Maria C B Gonçalves; Juliana Corrêa-Velloso; Micheli M Pillat; Héllio D N de Souza; Henning Ulrich
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

Review 10.  Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors.

Authors:  Ana M Sebastião; Nádia Rei; Joaquim A Ribeiro
Journal:  Front Pharmacol       Date:  2018-04-16       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.